Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Technology and expertise align, resulting in novel potential treatment for lethal prostate cancer

Technology and expertise align, resulting in novel potential treatment for lethal prostate cancer

Stories Feb 4, 2016 4 minutes

License agreement aims to advance new line of drug therapy.

One out of every six to seven men will develop prostate cancer in his lifetime1. Of those prostate cancer patients, about 25 to 30 per cent will present late or have a recurrence that is typically indicative of metastatic advanced disease, meaning the cancer has spread throughout the body and is virtually incurable. Such difficult cases have propelled Vancouver Prostate Centre (VPC) scientists Dr. Artem Cherkasov and Dr. Paul Rennie to combine their expertise in an effort to find molecules that may one day address the problem of prostate cancer drug resistance and disease recurrence. Their breakthrough research has been validated by a license agreement with pharmaceutical company Roche.

Prostate cancer growth is dependent on the interaction of androgens (i.e. testosterone and dihydrotestosterone) with the androgen receptor (AR) – a nuclear receptor found within cells that, when activated, controls the biological effects of androgens. AR signalling is the main driver of most progressive prostate cancers.

“The scenario we see is a man whose cancer has reoccurred, who has been treated with conventional anti-hormone therapies, which then eventually fail, usually through mutations or through a variety of mechanisms,” explains Dr. Rennie, director of laboratory research at the VPC, which is a Vancouver Coastal Health Research Institute research centre. “Every other anti-androgen (receptor) drug binds to the exact same androgen-binding site – some drugs better than others through differences and properties, but when resistance arises in that region of the AR because it has mutated, they simply fail.”

Dr. Rennie and Dr. Cherkasov’s approach to the problem of drug resistance is unique in two key ways. First, the researchers targeted the location at which the AR actually binds to the DNA, and therefore the drug directly interferes with AR’s transcriptional function, unlike all previous anti-androgens binding to the androgen-binding site. Second, they were able to create a virtual model of the actual pocket in the DNA binding domain that has not been seen before. Having such a pocket allows them to attempt fitting chemicals into it. As a result, they are able to develop drugs with the potential to overcome resistance mechanisms seen with existing therapies.

“Our drugs target that DNA-binding domain site, which enables them to work even when the tumours have a form of the AR that’s now resistant to the conventional drugs,” says Dr. Rennie, who is also a professor in the Department of Urologic Sciences at the University of British Columbia. 

“Our drugs target every potential form of AR that we’ve encountered.”

Dr. Cherkasov, a senior research scientist at the VPC and associate professor in the Department of Urologic Sciences at UBC, and his research team have developed a variety of mathematical modelling suites that enable them to model millions of potential small molecule structures to find those in virtual reality that may work against a particular target.

“We see where we’re going and then we develop very specific, precise, and accurate small molecules that will target the receptor in new ways, at new sites, and moreover, in the sites where the receptor is less likely to adapt to the attack,” says Dr. Cherkasov. “We have all kinds of approaches and computations to validate our predictions,” he adds. “And only when I’m very certain that the computer has given me a good answer, then we go out and make the potential drug.”

“We’re inventing new compounds that don’t even exist in nature. We bring them into existence in 3D virtual reality. We actually make them and test them and they work.”

Dr. Cherkasov and Dr. Rennie joined forces five years ago. Dr. Cherkasov handles modelling and Dr. Rennie is responsible for the biology side of their research. Dr. Cherkasov likens their combined efforts to a successful military offensive.

“It’s one thing to bombard a field brutally; it’s another to have a satellite image and use guided missiles to do so. Our approach is the latter,” he says. “I provide this satellite guidance for missiles and Dr. Rennie provides the ground support for the war on cancer. Our working together is truly mutually propelling and it’s a real synergy – that’s why we’re so successful.”

The research team’s licensing deal with Roche will provide them with the expertise and resources to chemically modify, improve upon, and test their drug leads. Their access to the VPC’s world-class models and lab technology, in addition to high throughput screening technologies, gene reading, and the field of computational lab discovery created by Dr. Cherkasov, have together contributed to their successes thus far.

“We are successful because of all of these things combined,” he says. “The technology matured enough at every front to be able to deliver this.” 

 

1 Information for Men Newly Diagnosed with Prostate Cancer 

Researchers

Paul Rennie
Artem Cherkasov

Related Articles

Discovery offers new insights to understand and treat prostate cancer

Welcoming the new M. H. Mohseni Institute of Urologic Sciences to VCHRI

Prostate Centre director’s new vision for urologic sciences research

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Vancouver Prostate Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy